<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intratumor <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>-<z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells within a <z:e sem="disease" ids="C1298180" disease_type="Neoplastic Process" abbrv="">single tumor</z:e>-is considered one of the most problematic factors of treatment </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001425'>Genetic heterogeneity</z:hpo>, such as in <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> and chromosome aberrations, is a common characteristic of human <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> and is probably the basis of biological <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Using mutations in APC, TP53 and KRAS as markers to identify distinct <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> subpopulations, we analyzed a total of 42 primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues and six paired <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> with multipoint microsampling, which enabled analysis of mutation patterns and allelic imbalances with a resolution of 0.01Â mm(2) (about 200 cells) </plain></SENT>
<SENT sid="3" pm="."><plain>There was usually more than one subpopulation in each <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Only two of 15 (13.3%) cases with three gene mutations and eight of 27 (29.6%) cases with two gene mutations had a single subpopulation </plain></SENT>
<SENT sid="5" pm="."><plain>Cells with mutations in <z:hpo ids='HP_0000001'>all</z:hpo> of the examined genes usually constituted the major population </plain></SENT>
<SENT sid="6" pm="."><plain>Multipoint microsampling of six primary and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumor</z:e> pairs revealed that the majority of discrepancies in mutation patterns found with the bulk tissue analysis were due to loss of subpopulations in the metastatic tissues </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, multipoint microsampling uncovered substantial changes in subpopulations that were not detected with bulk tissue analysis </plain></SENT>
<SENT sid="8" pm="."><plain>Specifically, the proportion of KRAS mutation-negative subpopulations increased in the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e> of four cases </plain></SENT>
<SENT sid="9" pm="."><plain>Because KRAS mutation status is linked to cetuximab/panitumumab efficacy, subpopulation dynamics could lead to differences in response to cetuximab/panitumumab in primary versus <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e> </plain></SENT>
</text></document>